Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.01 (5.556%)
Market Cap: £2.44m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

26 Sep 2006 16:46

Azure Holdings PLC26 September 2006 Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2006 Chairman's statement I am pleased to present the interim accounts for the six months ended 30 June2006. In the six months to 30 June 2006 the Company announced a loss after taxation of£138,000 (2005: £74,000). The figures should not reflect the future of the Company, which hopefully willmove forward successfully as ValiRx plc from early next month, because, asannounced on 11 September 2006, the reverse acquisition of ValiRx Limited hasbeen agreed and is subject to shareholders approval at the EGM scheduled for 2October 2006. If all the resolutions at that meeting are approved, the Company will retain itsAIM quotation and I will resign as Chairman leaving the new board and GerryDesler, Finance Director from the old board, to run the Company. Barry GoldChairman 26 September 2006 Azure Holdings plc Profit and Loss Account for the six months ended 30 June 2006 6 months ended 6 months ended Year ended 31 30 June 2006 30 June 2005 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000 Turnover - - - Administrative expenses (138) (74) (134) Operating loss (138) (74) (134) Loss on ordinary activities before taxation (138) (74) (134) Tax on loss on ordinary activities - - - Loss on ordinary activities after taxation (138) (74) (134) Retained loss for the period (138) (74) (134) Loss per ordinary share (0.12p) (0.15p) (0.28p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains and losses. Azure Holdings plc Balance Sheet as at 30 June 2006 30 June 2006 30 June 2005 31 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000Current assetsDebtors 9 3 1Cash at bank and in hand 127 1 1 136 4 2 Creditors: amounts falling due within one year (103) (147) (205) Net current assets/(liabilities) 33 (143) (203) Total assets less current liabilities 33 (143) (203) Net (liabilities)/assets 33 (143) (203) Capital and reservesCalled up Share Capital 6,271 5,475 5,475Share Premium 9,858 10,279 10,279Profit and loss account (16,096) (15,897) (15,957) Equity shareholders funds 33 (143) (203) Azure Holdings plc Cash Flow Statement for the six months ended 30 June 2006 6 months ended 6 months ended 30 June 2006 30 June 2005 (unaudited) (unaudited) £'000 £'000Net cash inflow (outflow) from operating activities (249) (13) FinancingIssue of ordinary shares 796 - Share premium reduction arising onconversion of loan stock (421) - Increase/(Decrease) in cash 126 (13) Azure Holdings plc Notes to the Interim Results 1. The interim results are unaudited and do not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. Thefigures for the year ended 31 December 2005 have been extracted from thestatutory accounts filed with the registrar of companies on which the auditorsgave an unqualified report. 2. The interim results have been prepared using the accountingpolicies set out in the statutory accounts for the year ended 31 December 2005. 3. The comparative figures for the unaudited interim results for theperiod ended 30 June 2005 are stated as announced on 27 September 2005. 4. Loss per share The loss per share for the six months ended 30 June 2006 has been calculated onthe basis of the loss after taxation for the period of £138,000 (2005: £74,000) and the weighted average number of shares in issue during the period of118,717,810 (2005: 48,317,569). . 5. The directors do not propose to pay a dividend for the period. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Aug 20177:00 amRNSConvertible Loan Facility
2nd Aug 20177:00 amRNSConversion of Loan Note
28th Jul 20177:00 amRNSLicencing Agreement
22nd Jun 20177:00 amRNSFormation of & Appointments to an Advisory Board
15th Jun 20177:00 amRNSValiSeek Development Update - Recruitment Closes
1st Jun 201711:00 amRNSYorkville CLN Conversion
31st May 201711:00 amRNSHardman Research:Developing novel cancer therapies
30th May 201710:34 amRNSResult of AGM
24th May 20177:00 amRNSNOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE
5th May 20175:28 pmRNSNotice of AGM
5th May 20177:00 amRNSFinal Results
27th Apr 201710:07 amRNSRe: SHARES Magazine Supplement on ValiRx website
19th Apr 20179:00 amRNSChange of Registered Office
15th Mar 20179:33 amRNSDirector/PDMR Shareholding
8th Mar 20177:00 amRNSValiSeek Clinical Development Update
2nd Mar 20177:00 amRNSDirector/PDMR Shareholding
1st Mar 20171:37 pmRNSPlacing to raise £1.16m and Proposed Subscription
28th Feb 20177:00 amRNSPublication of Peer-Reviewed Articles on VAL401
11th Jan 20177:00 amRNSCLINICAL TRIAL UPDATE - Positive VAL201 Results
30th Dec 20167:00 amRNSYorkville CLN Conversion
8th Dec 20167:00 amRNSEuropean Patent Granted for Lead Compound VAL201
2nd Dec 20164:15 pmRNSConvertible Loan Facility
1st Dec 20167:00 amRNSValiSeek Clinical Development Update
29th Nov 20167:00 amRNSQuarterly Update on Clinical Developments
3rd Nov 20167:00 amRNSValiSeek Clinical Development Update
28th Oct 20169:00 amRNSCorporate Video re Clinical Status Q4, 2016
25th Oct 20167:00 amRNSPatent Update
13th Oct 20164:20 pmRNSHolding(s) in Company
13th Oct 20164:20 pmRNSHolding(s) in Company
13th Oct 20167:00 amRNSUpdate on Recent Presentations
12th Oct 201611:15 amRNSResult of General Meeting
5th Oct 20163:42 pmRNSCLN Conversion
28th Sep 201611:09 amRNSNotice of GM
27th Sep 20167:00 amRNSHalf-year Report
26th Sep 20167:00 amRNSValiRx selected for The Parliamentary Review 2016
13th Sep 20167:00 amRNSQuarterly Update on Clinical Developments
2nd Sep 20162:10 pmRNSPlacing, issue of warrants & Convertible Loan
11th Aug 20167:00 amRNSValiSeek Clinical Development Update
4th Aug 201611:32 amRNSIssue of Equity
28th Jul 20167:00 amRNSNotification of New Zealand Patent Grant Allowance
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.